Description
BSE announces listing of 800 Commercial Papers issued by Kotak Mahindra Prime Limited on private placement basis, with face value of Rs. 5 lakhs each, effective December 15, 2025.
Summary
BSE has listed 800 new Commercial Papers issued by Kotak Mahindra Prime Limited on a private placement basis in the BSE Debt segment effective December 15, 2025. The instruments have a face value of Rs. 5,00,000 each, issued at Rs. 4,68,008, and will mature on December 9, 2026. The securities carry CRISIL A1+ and ICRA A1+ credit ratings and will trade in dematerialized form only.
Key Points
- Quantity: 800 Commercial Papers listed
- Face Value: Rs. 5,00,000 per instrument
- Issue Price: Rs. 4,68,008 per instrument
- Scrip Code: 730739
- Scrip ID: KMP101225
- ISIN: INE916D146I6 (further listing under same ISIN)
- Credit Rating: CRISIL A1+, ICRA A1+
- Market Lot: 1
- Trading denomination: Rs. 5 lakhs and multiples thereof
- Tick size: 1 paise
- Issuing and Paying Agent: Kotak Mahindra Bank Ltd
Regulatory Changes
No regulatory changes introduced. This is a routine listing notification.
Compliance Requirements
- Trading members must trade these securities only in dematerialized form under ISIN INE916D146I6
- Trading must be conducted in standard denomination of Rs. 5 lakhs and multiples thereof
- Securities to be traded exclusively on BSE Debt segment
Important Dates
- Listing Date: December 15, 2025
- Date of Allotment: December 15, 2025
- Redemption Date: December 9, 2026
- Tenor: Approximately 359 days
Impact Assessment
This is a routine commercial paper listing with minimal market impact. The instruments are institutional debt securities traded on the debt segment and do not affect equity market operations. The listing expands short-term debt investment options for institutional investors. Trading members of the debt segment can contact BSE debt department at specified phone numbers (22728352/8597/8995/5753/8915) for clarifications.
Impact Justification
Routine commercial paper listing on debt segment with standard terms, limited to institutional investors, no impact on equity markets or broader trading operations